Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $195
Revolution Medicines
Revolution Medicines RVMD | 0.00 |
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:
RVMD) with a Outperform and raises the price target from $165 to $195.
